Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNITE: Human Urinary Kallidinogenase for Acute Ischemic Stroke
NCT06848894Enrolling by invitation
- Sponsor
- Beijing Tiantan Hospital
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Randomised trial of human urinary kallidinogenase + Shuxuening injection in ischemic stroke (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Proportion of a favorable outcome (mRS 0-2) at 90 days. Started Apr 2025; status: enrolling by invitation.
02
Drugs
human urinary kallidinogenase + Shuxuening injection
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06848894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06848894.